From Newsgroup: rec.music.classical

<div>Objectives: This study evaluated the temporal association between atrial high-rate episodes (AHREs) and sustained ventricular arrhythmias (VAs) in a remotely monitored cohort with implantable cardioverter-defibrillators (ICD) with and/or without cardiac resynchronization therapy with a defibrillator (CRT-D).</div><div></div><div></div><div></div><div></div><div></div><div>Download The Episode 1.41 Full Movie Italian Dubbed In Torrent</div><div></div><div>DOWNLOAD: https://t.co/zOK1dDEKcv </div><div></div><div></div><div>Methods: This study analyzed data of patients with ICDs and CRT-Ds from the nationwide Home Monitoring Expert Alliance network. The cohort included 2,435 patients with a median follow-up of 25 months (interquartile range: 13 to 42 months) and age 70 years (range 61 to 77 years); 19.7% were women, 51.4% had coronary artery disease, and 45.2% had a CRT-D. There were 3,410 appropriate VA episodes; 498 (14.6%) were preceded by AHREs within 48 h; in 85.5% of this group, AHREs were still ongoing at episode onset.</div><div></div><div></div><div>Secondary efficacy end points included: the incidence rate of spontaneous bleeds (episodes per patient-time), the interval between randomisation and the first bleeding episode after randomisation, the mean duration of spontaneous bleeding episodes, the mean number of infusions per spontaneous bleeding episode, and the mean dose of vWF/FVIII concentrate administered per spontaneous bleeding episode (only for bleeding episodes requiring treatment with FVIII/vWF concentrates).</div><div></div><div></div><div>The mean time from baseline to the first bleeding episode was 66.033.7 days vs 34.610.5 days in the ODT group. The median event-free interval was 23 days in both groups. According to a Kaplan-Meier analysis, the difference was not significantly different (p =0.2795) (Figure 2).</div><div></div><div></div><div>More patients in the ODT group (100%) than in the PRO group (60%) experienced spontaneous bleedings during the study (primary efficacy end point). However, the discontinuation of 4 PRO patients with no bleeds should be taken into account when analysing this result. Even excluding 112 of the 172 bleeds in the ODT group as occurring all in one single patient, the number of bleeding episodes of the ODT group was still 2-fold higher than the number of the PRO group (60 vs 32, respectively), although in that case the statistical relevance of the difference is probably lower. The mean number of bleeds per patient, the incidence rate and the overall risk of bleeds were in the expected ranges31 and lower in the PRO group, with the exception of gastrointestinal haemorrhage. The reasons why gastrointestinal bleeds seemed to respond poorly to PRO treatment remains unclear, although that could be partially ascribed to the propensity for this bleeding type, including a possible underlying gastrointestinal angiodysplasia, of the single outlier patient who experienced most (80%) of the episodes.</div><div></div><div></div><div>While there was no significant difference in the time to the first bleeding episode between groups, the duration of bleeds was longer in the PRO group for all bleeding types except epistaxis. This could be explained by the fact that almost all bleeds in the ODT group required treatment with vWF/FVIII concentrate, whereas less than half of the bleeding episodes in the PRO group required additional treatment.</div><div></div><div></div><div>SBP and DBP were similarly reduced by the 3 treatments (p </div><div></div><div></div><div>Despite similar BP lowering T and R were more effective than A in preventing new episodes of AF and in reducing their severity as documented by the slower ventricular rate and by the less increase in plasma cTn-I; however, the effect of T was greater than that of R. This could be related to some specific mechanism of T.</div><div></div><div></div><div>Laboratory evidence of antiphospholipid antibodies (APLA) in patients with a first episode of venous thromboembolism (VTE) is often considered an indication for indefinite anticoagulant therapy, but it is uncertain if this practice is justified. We performed a systematic review to determine whether the presence of APLA in patients with a first VTE is associated with an increased risk of recurrence. We searched PubMed, CINAHL, Cochrane, EMBASE, and Web of Knowledge through February 2012 and included prospective studies that met prespecified design criteria. There were 109 recurrent VTE in 588 patients with APLA and 374 recurrent VTE in 1914 patients without APLA (relative risk 1.41; 95% confidence interval [CI], 0.99 to 2.36). The unadjusted risk ratio for recurrent VTE after stopping anticoagulant therapy in patients with an anticardiolipin antibody was 1.53 (95% CI, 0.76-3.11), and with a lupus anticoagulant was 2.83 (95% CI, 0.83-9.64). All studies had important methodologic limitations and we judged the overall quality of the evidence as very low. Although a positive APLA test appears to predict an increased risk of recurrence in patients with a first VTE, the strength of this association is uncertain because the available evidence is of very low quality.</div><div></div><div></div><div>Three studies included only patients with unprovoked VTE,14,16,18 whereas 5 studies included both patients with provoked as well as unprovoked VTE.8,15,17,19,20 Two studies described the proportion of patients with cancer; they included 3% and 5% of patients with malignancy, respectively15,19 (Table 3). The original episode of VTE was either a DVT (usually proximal) or a PE in 7 studies,8,14,16-20 and had to be a DVT in 1 study.15 Patients who were known to have APLA (there was no routine preenrollment screening in any study) were excluded from enrollment in 4 studies,14,16-18 and not excluded in 2 studies8,15 ; this information was not available for 2 studies.19,20</div><div></div><div></div><div>Data obtained from an earlier report (ref: Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J of Med. 1995;332:1661-1665.); all patients in that report were not included in the APLA analysis.</div><div></div><div></div><div>The 8 studies reported on the association between an APLA (ACLA, LA, or both) and recurrent VTE in patients who were not on anticoagulants (Table 3). The study by Bank et al, which included the smallest number of patients, reported no episodes of VTE in 7 patients with APLA. Therefore, a RR could not be calculated for this study and it was not included in the meta-analysis (Figure 2). In the 7 included studies, there were 109 recurrent VTE in 588 patients with APLA and 374 recurrent VTE in 1914 patients without APLA, yielding an unadjusted RR of 1.41 (95% confidence interval [CI] 0.99-2.36; I2 = 49%; P for heterogeneity = .09).</div><div></div><div></div><div>Six studies specified whether or not patients had ACLA.8,15-17,19,20 In 3 of these, however, there were no episodes of VTE in a total of 27 patients with ACLA (Table 3). Therefore, a RR could not be calculated for these 3 studies and they are not included in the meta-analysis for this subgroup (Figure 3). In the 3 included studies, there were 45 recurrent VTE events in 169 patients with ACLA and 255 recurrent VTE in 1230 patients without APLA, yielding an unadjusted RR of 1.53 (95% CI 0.76-3.11; I2 = 68%; P for heterogeneity = .04).</div><div></div><div></div><div>Four studies specified whether or not patients had an LA.8,15-17 In 1 of these, however, there were no episodes of VTE in 2 patients with an LA(Table 3). Therefore, a RR could not be calculated for this study and it is not included in the meta-analysis (Figure 4). In the 3 included studies, there were 5 recurrent VTE in 19 patients with an LA and 24 recurrent VTE in 229 patients without an APLA, yielding an unadjusted RR of 2.83 (95% CI 0.83-9.64; I2 = 0%; P for heterogeneity = .44).</div><div></div><div></div><div>Two studies reported on the association between APLA (ACLA, LA, or both) and recurrent VTE in patients who were on anticoagulants.8,19 The study by Ginsberg reported no episodes of VTE in 16 patients with APLA. Therefore, a RR could not be calculated for this study. In the study by Walhander, among patients randomized to extended anticoagulation with ximelagatran, there were 2 recurrent VTE in 45 patients with APLA (only ACLA was assessed) and 5 recurrent VTE in 483 patients without an ACLA, yielding an unadjusted RR of 3.16 (95% CI 0.75-13.3).</div><div></div><div></div><div>Since AM reflects the total circulating level of RIS and 9-OH-RIS, while the RIS/9-OH-RIS ratio is the fraction of RIS to its metabolite, which is also marketed as the antipsychotic paliperidone, and has been found to be safe and effective in first-episode schizophrenia [33], and given that the latter ratio was predicted by our mixed effects logistic regression models only by RIS daily dose, while AM was predicted by most measures entered in the model, including RIS daily dose, which was the most significantly associated parameter in the model, RIS daily dose is the measure that should most be considered in treating patients with disruptive/impulsive/CDs of pediatric age.</div><div></div><div></div><div>Background and Objectives: 1) To identify the sociodemographic, anamnestic characteristics and presentation symptoms of patients, at the time of first hospitalization, associated with a discharge diagnosis of schizophrenic versus non-schizophrenic psychoses; 2) to define risk factors, at the time of the first admission, for a rehospitalization, regardless of reasons for readmission; 3) to assess the diagnostic stability between first and second hospitalization. </div><div></div><div>Methods: This study includes 245 patients first admitted to the University Psychiatric Clinic of Novara in a period of seven years, discharged with a diagnosis of psychosis as reported in the Discharge Register (ICD-9-CM codes 290-299). Data were collected by consulting medical records and registers of community-based services of the South Novara Mental Health Department. A logistic regression model was used to determine the characteristics associated with a discharge diagnosis of schizophrenia. The relationship between the risk of rehospitalization and patients characteristics was studied using Cox,s regression analysis. </div><div></div><div>Results: Risk factors for a discharge diagnosis of schizophrenia were age, compulsory admission, positive symptoms, and previous non-psychotic psychiatric episodes. Risk factors for rehospitalization were a diagnosis of schizophrenia, an age of less than 40 years, the absence of a stable affective relationship, and living with the family of origin. The 92% of the patients diagnosed as schizophrenic on the first hospitalization had the same diagnosis on readmission. </div><div></div><div>Conclusions: Schizophrenia differs from other psychoses in terms of the greater prevalence of both some symptomatological characteristics and an history of previous non psychotic episodes. Some sociodemographic and clinical characteristics at the time of the first hospitalization can provide indications useful in preventing rehospitalization.</div><div></div><div> dd2b598166</div>
--- Synchronet 3.21a-Linux NewsLink 1.2